Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02127125 · ClinicalTrials.gov registry record · Phase 2

Mechanism of Microbiome-induced Insulin Resistance in Humans (Aim2)

A Phase 2 study of Insulin Sensitivity, sponsored by The University of Texas Health Science Center at San Antonio.

Completed
Registry status
Phase 2
Development phase
69
Enrollment target
1
Study location

NCT02127125: Completed Phase 2 study of Insulin Sensitivity, sponsored by The University of Texas Health Science Center at San Antonio.

NCT02127125 is a Phase 2 study of Insulin Sensitivity that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 69 participants, roughly in line with the 71-participant average among 29 other Insulin Sensitivity trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02127125, a Phase 2 study of Insulin Sensitivity, has completed, sponsored by The University of Texas Health Science Center at San Antonio.

COMPLETED
Registry status
Phase 2
Development phase
69 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine whether microbiome modulation and an experimental reduction in plasma LPS concentration improve inflammation and insulin action in insulin resistant (obese and T2DM) subjects.

Primary Outcome

Insulin sensitivity in skeletal muscle (M value) as measured by hyperinsulinemic euglycemic clamp study. The clamp study tests the ability of peripheral tissues such as skeletal muscle to uptake glucose in response to a constant insulin stimulus, which give a measure of sensitivity to insulin action. 60 mU/m2\*min insulin was infused into subjects for 180 minutes with concomitant adjustment of glucose infusion rate using D20 glucose to maintain a clamped plasma glucose concentration of 100 mg/dL

Conditions Studied

Interventions

  • DRUG Maltodextrin
  • DRUG Synbiotic
  • DRUG Sevelamer

Study Locations (1)

Texas

  • Audie L. Murphy VA Hospital, STVHCS - San Antonio

Trial Details

FieldValue
Enrollment Target 69 participants
Start Date 2014-04-10
Est. Completion 2018-09-10
Phase Phase 2

What the finished NCT02127125 record still lists

NCT02127125 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 69 participants, a relatively small participant target, roughly in line with the 71-participant average among 29 other Insulin Sensitivity trials with a reported enrollment target.

The record links to 1 condition, with Insulin Sensitivity appearing as the primary indexed condition, and to 3 interventions - of which Maltodextrin is the first listed.

NCT02127125 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT02127125 about?

NCT02127125 is a clinical study titled "Mechanism of Microbiome-induced Insulin Resistance in Humans (Aim2)". The purpose of this study is to determine whether microbiome modulation and an experimental reduction in plasma LPS concentration improve inflammation and insulin action in insulin resistant (obese and T2DM) subjects.

What is the current status of trial NCT02127125?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 69 participants. The study started on 2014-04-10. Estimated completion is 2018-09-10.

What conditions does trial NCT02127125 study?

This clinical trial studies the following conditions: Insulin Sensitivity.

What interventions are being tested in trial NCT02127125?

The interventions under investigation include: Maltodextrin (DRUG), Synbiotic (DRUG), Sevelamer (DRUG).

Who is sponsoring clinical trial NCT02127125?

This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02127125 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Insulin Sensitivity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02127125's enrollment target sits among peer trials

69 10th of 29 higher than 20 of 29 other Insulin Sensitivity trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Insulin Sensitivity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04020575 · 69 participants · Phase 1

    Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)

  • NCT04163614 · 69 participants · NA

    Blood Pressure Slopes and Ultrafiltration in Hemodialysis Patients

  • NCT04164641 · 69 participants · NA

    Noraxon myoRESEARCH™ Software Gait Analysis Evaluation and Orthotic Gait Correction in Reducing Diabetic Foot Ulceration Or Subsequent Amputation in Patients With a History of a Diabetic Foot Ulceration

  • NCT04493372 · 69 participants · NA

    Deciphering Preserved Autonomic Function After Spinal Cord Injury

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02127125, the US trial registry maintained by the National Library of Medicine. NCT02127125 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.